Alphamab Oncology

As of December 31, 2025, Alphamab Oncology carries a market capitalization of 9.49B, placing it among publicly traded companies globally. Its enterprise value stands at 8.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alphamab Oncology's next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Alphamab Oncology has 968.57M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Alphamab Oncology maintains a current ratio of 5.67, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Alphamab Oncology's stock has declined approximately 52.49% over the past 52 weeks. The 50-day moving average sits at 8.04, while the 200-day moving average is 8.57.

As of December 31, 2025, Alphamab Oncology holds 1.50B in cash and equivalents against 136.86M in total debt, resulting in a net debt position of -155.94M. Total book value stands at 1.90B, with working capital of 1.46B providing operational flexibility.